Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL705473 | 0.92 | TDP1 (0.32) | NT5E | |
| SCHEMBL706581 | 0.86 | P2RY14 (0.34) | P2RY14NT5E | |
| SCHEMBL706580 | 0.84 | NT5E (0.35) | P2RY14NT5E | |
| SCHEMBL702852 | 0.83 | NT5E (0.36) | P2RY14NT5E | |
| SCHEMBL702851 | 0.79 | NT5E (0.32) | P2RY14NT5E | |
| SCHEMBL705316 | 0.78 | P2RY6 (0.34) | P2RY14NT5E | |
| SCHEMBL705472 | 0.76 | TDP1 (0.35) | P2RY14NT5E | |
| SCHEMBL707766 | 0.73 | TDP1 (0.33) | NT5E | |
| SCHEMBL701863 | 0.72 | SLC28A1 (0.41) | P2RY14NT5E | |
| SCHEMBL705299 | 0.72 | TDP1 (0.38) | P2RY14NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670896-B1 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS INC (US) | 2015-01-07 | — | — | EP | disclosed |
| US-20140357856-A1 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-8791083-B2 | Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry | ISIS PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| EP-1562971-B1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | ISIS PHARMACEUTICALS INC (US) | 2014-02-12 | — | — | EP | disclosed |
| US-8124745-B2 | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation | ISIS PHARMACEUTICALS, INC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100216982-A1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | Isis Pharmaceutiacls, Inc. (US) | 2010-08-26 | — | — | US | disclosed |
| US-7696345-B2 | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation | ISIS PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090258931-A1 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| EP-1670896-A4 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS INC (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20080039618-A1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | ALLERSON CHARLES | 2008-02-14 | — | — | US | disclosed |
| EP-1670896-A2 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050142581-A1 | Microrna as ligands and target molecules | ISIS PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| US-20050074801-A1 | Nucleosides; solid phase synthesis; biochemical conjugation; for lowering cholesterol, triglyceride, plasma leptin, glucose, and/or plasma insulin levels; for lowering body weight | ISIS PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| WO-2005023986-A2 | MICRORNA AS LIGANDS AND TARGET MOLECULES | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023995-A2 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20040171570-A1 | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation | IONIS PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258931-A1 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | NSUN3, NSUN2, NOP2 | P2RY14 4661/4885NT5E 704/4885 |
| US-20040171570-A1 | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation | HNRNPC, SNRPE, IGF2BP1 | P2RY14 4228/4885NT5E 3913/4885 |
| US-20050074801-A1 | Nucleosides; solid phase synthesis; biochemical conjugation; for lowering cholesterol, triglyceride, plasma leptin, glucose, and/or plasma insulin levels; for lowering body weight | RNGTT, NSUN3, RNMT | P2RY14 4694/4885NT5E 405/4885 |
| US-20100216982-A1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | HNRNPC, SNRPE, IGF2BP1 | P2RY14 4228/4885NT5E 3913/4885 |
| US-20080039618-A1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | HNRNPC, SNRPE, IGF2BP1 | P2RY14 4228/4885NT5E 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.